Dr. Reddy's Laboratories Ltd.

As of June 30, 2026, Dr. Reddy's Laboratories Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR carries a market capitalization of 63.17B, placing it among publicly traded companies globally. Its enterprise value stands at 62.83B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Dr. Reddy's Laboratories Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR's next confirmed earnings release is scheduled for October 23, 2026.

As of June 30, 2026, Dr. Reddy's Laboratories Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR has 4.94B shares outstanding.

As of June 30, 2026, Dr. Reddy's Laboratories Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR trades at a trailing price-to-earnings ratio of 27.68. The price-to-sales ratio is 2.77, and the price-to-book ratio stands at 3.02.

As of June 30, 2026, Dr. Reddy's Laboratories Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR trades at an EV/EBITDA multiple of 21.07 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.47 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 34.46 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Dr. Reddy's Laboratories Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR trades at an EV/FCF ratio of 91.92, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 62.83B versus a market cap of 63.17B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Dr. Reddy's Laboratories Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR maintains a current ratio of 1.90, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 18.60, indicating elevated leverage, while an interest coverage ratio of 13.12 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Dr. Reddy's Laboratories Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR posted a return on equity (ROE) of 9.03, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.06 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 6.05, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.55, useful for judging operating efficiency across full business cycles. The company generates approximately 653,678.83 in revenue per employee across its workforce of 27,669.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.99 indicates how many times Dr. Reddy's Laboratories Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Dr. Reddy's Laboratories Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR recorded 468.40M in income tax expense. That works out to an effective tax rate of 20.77, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.26B, leaving 1.81B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Dr. Reddy's Laboratories Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR's stock has declined approximately 11.67% over the past 52 weeks. The 50-day moving average sits at 12.14, while the 200-day moving average is 12.35.

Over the twelve months ended June 30, 2026, Dr. Reddy's Laboratories Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR generated 18.09B in revenue and converted that into 1.81B in net income, yielding earnings per share of 0.46. EBITDA reached 2.98B, while operating income came in at 1.97B.

As of June 30, 2026, Dr. Reddy's Laboratories Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR holds 4.45B in cash and equivalents against 3.93B in total debt, resulting in a net debt position of 2.54B. Total book value stands at 20.94B, with working capital of 7.75B providing operational flexibility.

Dr. Reddy's Laboratories Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR produced 2.25B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.75B in capital expenditures, free cash flow totaled 503.47M - equivalent to 0.13 per share.

Over the twelve months ended June 30, 2026, Dr. Reddy's Laboratories Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR posted a gross margin of 53.00, reflecting its pricing power and cost economics. The operating margin of 10.89 and net profit margin of 10.00 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Dr. Reddy's Laboratories Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR paid dividends of 0.09 per share. The dividend payout ratio of 20.59 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 1.01, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.21, meaning Dr. Reddy's Laboratories Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dr. Reddy's Laboratories Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR's most recent stock split took place on November 7, 2024 with a 1:5 split ratio.

As of June 30, 2026, Dr. Reddy's Laboratories Ltd. ADR Unsponsored Brazilian Depositary Receipt Repr 0.16666667 ADR has an Altman Z-Score of 6.12, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.